We have recovered billions for our clientswith billions more to come
Retatrutide, developed by Eli Lilly under the code LY3437943, is a synthetic peptide that simultaneously activates three incretin and metabolic receptors: GLP-1, GIP, and glucagon
Our expert team will assess your unique needs and work with you to determine if GLP-1 therapy is right for you, alongside practical advice on nutrition, lifestyle changes, and ongoing support
TIRZEPATIDES THICKET OF FOLLOW-ON PATENTS Eli Lilly has built a thicket of follow-on patents in addition to the patent protecting the main compound tirzepatide (Figure 9)
Steiner was renowned for having discovered proinsulin while studying an insulinoma tumour extracted from a patient
What started as a breakthrough treatment for Type 2 diabetes has evolved into a phenomena reshaping employer health benefits, pharmacy operations, and insurance plans